
-
Hutchison China MediTech / Chi-Med NasdaqGS:HCM HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Location: Cheung Kong Center, Hong Kong, Hong Kong | Website: https://www.hutch-med.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.11B
Cash
838.8M
Avg Qtr Burn
N/A
Short % of Float
0.09%
Insider Ownership
0.13%
Institutional Own.
3.87%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELUNATE (Fruquintinib) (VEGFR 1/2/3) Details Colorectal cancer , Metastatic colorectal cancer, Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Quarterly sales | |
ORPATHYS (Savolitinib) Details Non-small cell lung carcinoma, Cancer, Colorectal cancer , Renal cell carcinoma, Gastric cancer | Approved Quarterly sales | |
HMPL-306 Details Hematologic malignancies, Blood cancer, Acute myeloid leukemia | Phase 3 Data readout | |
ORPATHYS (Savolitinib) (C-MET inhibitor) Details Renal cell carcinoma, Cancer, Gastric cancer | Phase 3 Data readout | |
ORPATHYS (Savolitinib) + osimertinib Details EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced Non-small cell lung carcinoma | Phase 3 Data readout | |
Sovleplenib (HMPL-523) (Syk inhibitor) Details Primary immune thrombocytopenia | Phase 3 Data readout | |
SULANDA (Surufatinib) Details Solid tumor/s, Neuroendocrine tumor, Pancreatic cancer, Cholangiocarcinoma, Cancer | Phase 3 Update | |
ELUNATE (Fruquintinib) + paclitaxel Details Cancer, Solid tumor/s, Gastroesophageal adenocarcinomas, Gastric cancer | Phase 3 Update | |
SULANDA (Surufatinib) + Camrelizumab Details Solid tumor/s, Pancreatic cancer, Cancer, Pancreatic ductal adenocarcinoma | Phase 2/3 Data readout | |
ELUNATE (Fruquintinib) + Sintilimab Details Solid tumor/s, Renal cell carcinoma, Cancer, Kidney cancer | Phase 2/3 Update | |
Sovleplenib (HMPL-523) (Syk inhibitor) Details Warm autoimmune hemolytic anemia | Phase 2/3 Update | |
ORPATHYS (Savolitinib) + TAGRISSO Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
Tazemetostat Details Follicular lymphoma | Phase 2 Data readout | |
Amdizalisib (HMPL-689) (PI3K) Details Non-Hodgkin lymphoma | Phase 2 Update | |
HMPL-453 (FGFR 1/2/3) Details Mesothelioma, Intrahepatic cholangiocarcinoma , Cancer | Phase 2 Update | |
Sovleplenib (HMPL-523) (Syk inhibitor) Details Warm autoimmune hemolytic anemia | Phase 1/2 Update | |
ELUNATE (Fruquintinib) + Sintilimab Details Solid tumor/s, Cancer, Endometrial cancer | Phase 1/2 Update | |
Sovleplenib (HMPL-523) (Syk inhibitor) Details Non-Hodgkin lymphoma | Phase 1/2 Initiation | |
HMPL-506 Details Cancer, Leukemia | Phase 1 Data readout |